Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideaki Bando

Showing results (71-80 of 186) with videos related to

Pageof 19
Sort By:
JCO Precision Oncology|April 18, 2024
Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening ProjectMasaya Hattori, Victoria Serelli-Lee, Yoichi Naito, et al.
Journal for Immunotherapy of Cancer|February 2, 2019
Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancerSaori Mishima, Akihito Kawazoe, Yoshiaki Nakamura, et al.
International Journal of Clinical Oncology|June 17, 2022
Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitorsYu Aoki, Akihito Kawazoe, Yohei Kubota, et al.
Journal of Global Oncology|May 10, 2019
Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With CancerKazunori Honda, Bishal Gyawali, Masashi Ando, et al.
American Journal of Clinical Oncology|May 24, 2021
Clinical Impact of Oral Intake in Second-line or Third-line Chemotherapy for 589 Patients With Advanced Gastric Cancer: A Retrospective Cohort StudyTakatsugu Ogata, Yukiya Narita, Ryosuke Kumanishi, et al.
Journal of Cancer Research and Clinical Oncology|March 22, 2022
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancerYuki Matsubara, Toshiki Masuishi, Takatsugu Ogata, et al.
Cancer Medicine|November 16, 2019
Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysisSeiichiro Mitani, Shigenori Kadowaki, Isao Oze, et al.
Clinical Colorectal Cancer|November 14, 2022
Trajectory for the Regulatory Approval of a Combination of Pertuzumab Plus Trastuzumab for Pre-treated HER2-positive Metastatic Colorectal Cancer Using Real-world DataYasutoshi Sakamoto, Hideaki Bando, Yoshiaki Nakamura, et al.
Cancer Science|April 29, 2026
Population-Based Identification of Clonal Hematopoiesis Using Peripheral Blood Whole-Genome Sequencing in JapanSungGi Chi, Ikuko N Motoike, Takao Fujisawa, et al.
ESMO Open|November 15, 2018
Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinomaSaori Mishima, Akihito Kawazoe, Hiroshi Matsumoto, et al.
Pageof 19

Showing results (71-80 of 186) with videos related to

Sort By:
Pageof 19
JCO Precision Oncology|April 18, 2024
Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening ProjectMasaya Hattori, Victoria Serelli-Lee, Yoichi Naito, et al.
Journal for Immunotherapy of Cancer|February 2, 2019
Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancerSaori Mishima, Akihito Kawazoe, Yoshiaki Nakamura, et al.
International Journal of Clinical Oncology|June 17, 2022
Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitorsYu Aoki, Akihito Kawazoe, Yohei Kubota, et al.
Journal of Global Oncology|May 10, 2019
Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With CancerKazunori Honda, Bishal Gyawali, Masashi Ando, et al.
American Journal of Clinical Oncology|May 24, 2021
Clinical Impact of Oral Intake in Second-line or Third-line Chemotherapy for 589 Patients With Advanced Gastric Cancer: A Retrospective Cohort StudyTakatsugu Ogata, Yukiya Narita, Ryosuke Kumanishi, et al.
Journal of Cancer Research and Clinical Oncology|March 22, 2022
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancerYuki Matsubara, Toshiki Masuishi, Takatsugu Ogata, et al.
Cancer Medicine|November 16, 2019
Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysisSeiichiro Mitani, Shigenori Kadowaki, Isao Oze, et al.
Clinical Colorectal Cancer|November 14, 2022
Trajectory for the Regulatory Approval of a Combination of Pertuzumab Plus Trastuzumab for Pre-treated HER2-positive Metastatic Colorectal Cancer Using Real-world DataYasutoshi Sakamoto, Hideaki Bando, Yoshiaki Nakamura, et al.
Cancer Science|April 29, 2026
Population-Based Identification of Clonal Hematopoiesis Using Peripheral Blood Whole-Genome Sequencing in JapanSungGi Chi, Ikuko N Motoike, Takao Fujisawa, et al.
ESMO Open|November 15, 2018
Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinomaSaori Mishima, Akihito Kawazoe, Hiroshi Matsumoto, et al.
Pageof 19